Floatz logo

Epirubicin

Prostate Adenocarcinoma

OHSU Knight Cancer InstitutePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
73/ 100

Competitive context

53 Active assets in the Prostate Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Degarelix
Canadian Cancer Trials Group
Phase 3BB
Zoladex
CancerCare Manitoba
Phase 3BB
LEUPROLIDE
Mayo Clinic
Phase 3BB
Flutamide
NRG Oncology
Phase 3BB
Psma-Hbed-Cc
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →